Advertisement

Journal of Endocrinological Investigation

, Volume 6, Issue 1, pp 41–45 | Cite as

Evidence for a therapeutic effect of dl-propranolol in benign and malignant insulinoma: report of three cases

  • I. Blum
  • Y. Rusecki
  • M. Doron
  • M. Lahav
  • Z. Laron
  • A. Atsmon
Case Report

Abstract

Two patients suffering from benign and one patient suffering from malignant insulinoma experienced frequent incapacitating hypoglycemic attacks which did not respond to treatment with streptozotocin, diazoxide and/or diphenylhydantoin. Dl-propranolol, in dosages ranging from 30–240 mg/day, successfully abolished the symptoms of hypoglycemia, prevented recurrent hypoglycemic attacks, and normalized blood glucose levels concomitant with a reduction in pulse rate to 60/min.The main mechanism of the drug’s effect seems to be the suppression of insulin release. However, other mechanisms may be involved such as increased peripheral insulin resistance. No side effects of treatment with dl-propranolol were noted. In patients suffering from insulinoma who are refractory to other forms of treatment, and for those who need symptomatic relief before surgery, dl-propranolol may play an important therapeutic role.

Key-words

dl-propranolol insulinoma insulin secretion insulin resistance glucagon 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Neri V., Bartorelli A., Faglia G. L’azione del propranolol sulla glicemia e sull’insulina immunoreattiva in una paziente affetta da insulinoma. Acta Diabetol. Lat. 6: 809, 1969.PubMedCrossRefGoogle Scholar
  2. 2.
    Blum I., Doron M., Laron Z., Atsmon A. Prevention of hypoglycemic attacks by propranolol in a patient suffering from insulinoma. Diabetes 24: 535, 1975.PubMedCrossRefGoogle Scholar
  3. 3.
    Shaklay M., Aderka D., Blum I., Laron Z., Asherov J., Doron M., Atsmon A., Pinkhas J. Suppression of hypoglycemic attacks and insulin release by propranolol in a patient with metastatic malignant insulinoma. Diabete Metab. 3: 155, 1977.Google Scholar
  4. 4.
    Blum I., Aderka D., Doron M., Laron Z. A comparison of dl-propranolol and d-propranolol in a patient with malignant insulinoma. N.Engl. J. Med. 299: 487, 1978.PubMedGoogle Scholar
  5. 5.
    Turner R.C., Oakley N.W., Nabarro J.D.N. Control of basal insulin secretion with special reference to the diagnosis of insulinomas. Br. Med. J. 2: 132, 1971.PubMedCentralPubMedCrossRefGoogle Scholar
  6. 6.
    Duckworth W.C., Kitabchi A.E. Direct measurement of plasma proinsulin in normal and diabetic subjects. Am. J. Med. 53:418, 1972.PubMedCrossRefGoogle Scholar
  7. 7.
    King K.C., Adam P.A.J., Yamaguchi K., Schwartz R. Insulin response to arginine in normal newborn infants and infants of diabetic mothers. Diabetes 23: 816, 1974.PubMedGoogle Scholar
  8. 8.
    Pi-Sunyer P.X., Van Itallie T.B., Zintel H.A. Insulin stimulatory tests in a patient with islet cell adenoma. Am. J. Surg. 118:95, 1969.PubMedCrossRefGoogle Scholar
  9. 9.
    Hales C.N., Randle P.J. Immunoassay of insulin with insulin-antibody precipitate. Biochem. J. 88: 137, 1963.PubMedCentralPubMedGoogle Scholar
  10. 10.
    Quabbe H.J. Modifikation der radioimmunologischen insulin bestimmung nach Hales und Randle. Diabetologia 5: 101, 1969.PubMedCrossRefGoogle Scholar
  11. 11.
    Cresto J.C., Lavine R.L., Fink G., Recant L. Gel filtration assay plasma proinsulin; comparison of insulin specific protease and gel filtration assays. Diabetes 23: 505, 1974.PubMedGoogle Scholar
  12. 12.
    Unger R.H., Aguilar-Parada E., Muller W.A., Eisentraut A.M. Studies in pancreatic alpha cell function in normal and diabetic subjects. J.Clin. Invest. 49:837, 1970.PubMedCentralPubMedCrossRefGoogle Scholar
  13. 13.
    Scandellari C., Zaccaria M., De Palo C., Sicolo N., Erie G., Federspil G. The effect of propranolol on hypoglycemia. Diabetologia 15:297, 1978.PubMedCrossRefGoogle Scholar
  14. 14.
    Woods S.C., Porte O. Neural control of the endocrine pancreas. Physiol. Rev. 54:596, 1974.PubMedGoogle Scholar
  15. 15.
    Samols E., Weir G.C. Adrenergic stimulation of pancreatic A, B and D cells alpha-adrenergic suppression and beta-adrenergic stimulation of somatostatin secretion, alpha-adrenergic stimulation of glucagon secretion in the perfused dog pancreas. J.Clin. Invest. 63:230, 1979.PubMedCentralPubMedCrossRefGoogle Scholar
  16. 16.
    Iversen J. Adrenergic receptors and the secretion of glucagon and insulin from the isolated perfused canine pancreas. J.Clin. Invest. 52:2102, 1973.PubMedCentralPubMedCrossRefGoogle Scholar
  17. 17.
    Cerasi E., Luft B., Efendic S. Effect of adrenergic blocking agents on insulin response to glucose infusion in man. Acta Endocrinol, (kbh.) 69: 335, 1972.Google Scholar
  18. 18.
    Harrower A.D.B., Nairn I.M., Strong J.A. Effect of propranolol on glucose tolerance in hyperthyroidism. Postgrad. Med. J. 53: 687, 1977.PubMedCentralPubMedCrossRefGoogle Scholar
  19. 19.
    Ortigosa J.L., Mendoza F., Argote R.M., Garcia G., Cervantes C., Parra A. Propranolol effect on plasma glucose, free fatty acid, insulin and growth hormone in Graves’ disease. Metabolism 25:1201, 1976.PubMedCrossRefGoogle Scholar
  20. 20.
    Wright A.D., Barber S.G., Kendall M.J., Poole P.H. Beta adrenoreceptor blocking drugs and blood sugar control in diabetes mellitus. Br. Med. J. 1: 159, 1979.PubMedCentralPubMedCrossRefGoogle Scholar
  21. 21.
    O’Dea K., Tank C., Kaplovitz H., Marino A.J. Development of insulin sensitivity in rat aorta after chronic propranolol treatment. Eur. J. Pharmacol. 47: 63, 1978.PubMedCrossRefGoogle Scholar
  22. 22.
    Exton J.H. Mechanisms involved in alpha-adrenergic effects of catecholamines on liver metabolism. J. Cyclic Nucleotide Res. 5: 277, 1979.PubMedGoogle Scholar
  23. 23.
    Ohneda A., Matsuda K., Horigome K., Ishii S., Yanbe A., Maruhama Y. Plasma glucagon in insulinoma. Acta Diabetol. Lat. 14:219, 1977.PubMedCrossRefGoogle Scholar
  24. 24.
    Gerich J.E., Langlois M., Noacco C., Schneider V., Forsham P.H. Adrenergic modulation of pancreatic glucagon secretion in man. J.Clin. Invest. 53: 1441, 1974.PubMedCentralPubMedCrossRefGoogle Scholar
  25. 25.
    Harvey W., Faloona G., Unger R. Effect of adrenergic blockade on exercise-induced hyperglucagonemia. Clin. Res. 20: 752A, 1972.Google Scholar
  26. 26.
    Walter R.M., Dudl R.J., Palmer J.P., Ensinck J.W. The effect of adrenergic blockade on the glucagon response to starvation and hypoglycemia in man. J. Clin. Invest. 54:1214, 1974.PubMedCentralPubMedCrossRefGoogle Scholar
  27. 27.
    Leonetti G., Zanchetti A. Studies of the absorption and removal of propranolol in hypertensive patients during therapy. Circulation 52: 313, 1975.PubMedCrossRefGoogle Scholar

Copyright information

© Italian Society of Endocrinology (SIE) 1983

Authors and Affiliations

  • I. Blum
    • 1
  • Y. Rusecki
    • 2
  • M. Doron
    • 3
    • 4
  • M. Lahav
    • 1
  • Z. Laron
    • 3
    • 4
  • A. Atsmon
    • 1
  1. 1.Department on Internal Medicine BBeilinson Medical CenterPetah TiqvaIsrael
  2. 2.Department on EndocrinologyBeilinson Medical CenterPetah TiqvaIsrael
  3. 3.Institute for Childhood and Adolescent EndocrinologyBeilinson Medical CenterPetah TiqvaIsrael
  4. 4.Sackler School of MedicineTel Aviv UniversityRamat AvivIsrael

Personalised recommendations